Welcome to our dedicated page for Agios Pharmaceuticals SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agios Pharmaceuticals, Inc. filings document the regulatory record of a Delaware, Nasdaq-listed commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its 8-K reports furnish operating results, product revenue updates for PYRUKYND® and AQVESME™, business highlights, investor presentations, and Regulation FD disclosures tied to mitapivat commercialization, clinical programs, and regulatory interactions.
Proxy and current-report filings cover annual-meeting proposals, director elections, board-class structure, committee assignments, stockholder voting matters, and compensatory arrangements for directors. Other disclosures address board appointments, pharmacovigilance communications involving PYRUKYND, exhibit filings, and Inline XBRL cover-page data.
Agios Pharmaceuticals executive Krishnan Viswanadhan, Chief Corp Dev & Strategy, reported several equity transactions on March 5, 2026 tied to restricted stock units (RSUs). He exercised 8,100 RSUs, converting them into 8,100 shares of common stock at a price of $0.00 per share, reflecting the nature of RSUs as equity awards rather than open-market purchases. Following this, 2,959 common shares were sold at $27.80 per share to cover tax withholding obligations related to the RSU vesting, under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, he directly held 16,200 RSUs and 5,141 common shares. The RSUs were granted on March 5, 2025, with the underlying shares scheduled to vest in three equal annual installments beginning March 5, 2026.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 reporting a proposed resale related to the vesting of 2,959 Restricted Stock Units into Common Stock. The vesting and proposed sale date is 03/05/2026, and the shares are listed on Nasdaq.
AGIOS PHARMACEUTICALS, INC. reported that Principal Accounting Officer Theodore James Washburn Jr. completed an open-market sale of common stock. On March 3, 2026, he sold 5,272 shares at a price of $28.88 per share and held 868 shares of common stock afterward.
AGIOS PHARMACEUTICALS, INC. Chief Executive Officer Brian Goff reported multiple equity-related transactions in company stock. On March 1, 2026, he received 48,000 restricted stock units and 174,000 stock options, each RSU representing the right to receive one share of common stock, with both awards vesting over several years as described.
On March 2, 2026, previously granted restricted stock units vested and were converted into common shares through exercises of 8,500, 18,000, and 13,000 RSUs. In connection with these vestings, he sold a total of 18,055 shares of common stock at $28.96 per share to cover tax withholding obligations, under durable automatic sale instructions referenced as compliant with Rule 10b5-1(c). After these transactions, he directly held 164,548 shares of AGIOS common stock.
AGIOS PHARMACEUTICALS, INC. Chief Legal Officer James William Burns reported multiple equity transactions. On March 1, 2026, he received grants of 14,000 restricted stock units and 52,000 stock options, both vesting over several years beginning March 1, 2027. On March 2, 2026, he exercised previously granted restricted stock units into common shares and reported open-market sales totaling 5,218 common shares at $28.96 per share to cover tax withholding obligations related to performance share vesting. These sales were executed under durable automatic sale instructions consistent with Rule 10b5-1(c). Following these transactions, he directly held 44,086 common shares.
AGIOS PHARMACEUTICALS Chief Medical Officer Sarah Gheuens reported multiple equity transactions. On March 2, 2026, she exercised restricted stock units into common shares and sold a total of 4,055 common shares at $28.96 per share to cover tax withholding obligations under pre-set Rule 10b5-1 instructions. Following these transactions, she directly held 74,406 shares of common stock. On March 1, 2026, she also received equity compensation grants of 14,000 and 22,000 restricted stock units and 52,000 stock options, all vesting over multi-year schedules beginning in March 2027.
AGIOS PHARMACEUTICALS, INC. Chief Financial Officer Cecilia Jones reported a mix of equity awards, vesting and related share sales. On March 1, 2026, she received 14,000 restricted stock units and stock options for 52,000 shares, with RSUs vesting in three equal annual installments and the option vesting 25% on March 1, 2027 and the remaining 75% in 36 equal monthly installments.
On March 2, 2026, multiple restricted stock unit tranches were exercised into common stock, and a total of 5,035 common shares were sold at $28.96 per share. Footnotes state these sales were made to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c) and included in prior restricted stock unit agreements. After these transactions, she directly owned 49,328 common shares of Agios common stock.
AGIOS PHARMACEUTICALS, INC. Chief Commercial Officer Tsveta Milanova reported a mix of equity grants, vesting, and tax-related share sales. On March 1, 2026, she received 14,000 restricted stock units and 52,000 stock options, with both awards vesting over multiple years starting March 1, 2027.
On March 2, 2026, previously granted restricted stock units vested, converting into 5,666 and 4,000 shares of common stock at no cost through derivative exercises. To cover tax withholding from these vestings, she sold 2,868 shares of common stock in open-market transactions at $28.96 per share under durable automatic Rule 10b5-1 instructions. After these trades, she continued to hold tens of thousands of shares directly.
AGIOS PHARMACEUTICALS, INC. principal accounting officer Theodore James Washburn Jr. reported multiple equity transactions linked to restricted stock units. On March 1, 2026, he received a grant of 8,452 restricted stock units, each representing a contingent right to one share of common stock, vesting in three equal annual installments beginning March 1, 2027.
On March 2, 2026, restricted stock units granted in 2023, 2024 and 2025 vested, with 2,350, 2,450 and 2,695 units respectively converting into common stock at no cost. To cover tax withholding obligations from these vestings, he sold a total of 2,223 shares of common stock in open-market transactions at $28.96 per share pursuant to durable automatic sale instructions under Rule 10b5‑1. Following these transactions, he held 6,140 common shares directly, including 75 shares acquired through the company’s employee stock purchase plan.
AGIOS PHARMACEUTICALS, INC. executive Krishnan Viswanadhan, Chief Corporate Development & Strategy, reported equity compensation grants rather than market purchases or sales. He received 14,000 restricted stock units, each representing a right to one share of common stock.
The restricted stock units were granted on March 1, 2026 and will vest in three equal annual installments beginning March 1, 2027. He was also granted stock options covering 52,000 shares at a per-share exercise price of $0.00, vesting 25% on March 1, 2027 and the remaining 75% in 36 equal monthly installments thereafter.